$3.47
2.44% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Inventiva - ADR Stock price

$3.47
-0.11 3.06% 1M
+1.02 41.83% 6M
+1.33 62.37% YTD
+0.31 9.96% 1Y
-9.95 74.11% 5Y
-9.95 74.11% 10Y
-9.95 74.11% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.08 2.44%
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Key metrics

Market capitalization $465.48m
Enterprise Value $416.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 39.23
P/S ratio (TTM) P/S ratio 43.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -47.37%
Revenue (TTM) Revenue $10.62m
EBIT (operating result TTM) EBIT $-110.82m
Free Cash Flow (TTM) Free Cash Flow $-99.63m
Cash position $111.53m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 24.84
EV/Sales forward 22.24
Short interest 0.28%
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Inventiva - ADR forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Inventiva - ADR forecast:

Buy
91%
Hold
9%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
47% 47%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
19% 19%
133%
- Research and Development Expense 102 102
18% 18%
957%
-104 -104
10% 10%
-981%
- Depreciation and Amortization 6.64 6.64
127% 127%
63%
EBIT (Operating Income) EBIT -111 -111
7% 7%
-1,043%
Net Profit -213 -213
67% 67%
-2,003%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
GlobeNewsWire
18 days ago
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's Management will participate in two upcoming inve...
Neutral
GlobeNewsWire
22 days ago
Daix (France),  New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equi...
Neutral
GlobeNewsWire
22 days ago
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders' Meeting.
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Employees 116
Founded 2011
Website inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today